-
公开(公告)号：US10363214B2
公开(公告)日：2019-07-30
申请号：US14324630
申请日：2014-07-07
申请人： Allergan, Inc.
IPC分类号： A61K39/395 , A61K9/19 , A61K9/48 , C07K16/22 , A61K9/00 , A61K9/16 , A61K47/36 , A61K31/712 , A61K39/00
摘要： Compositions and methods for treating dry age related macular degeneration (dry AMO) by administration to an intraocular location of an anti-neovascular agent (such as bevacizumab) in either a liquid or solid polymeric vehicle (or both), such as a biodegradable hyaluronic acid or PLGA (or PLA).
-
公开(公告)号：US20190015425A1
公开(公告)日：2019-01-17
申请号：US16132857
申请日：2018-09-17
申请人： Allergan, Inc.
发明人： Jane-Guo Shiah , Rahul Bhagat , Wendy M. Blanda , Thierry Nivaggioli , Lin Peng , David Chou , David A. Weber
摘要： The invention provides biodegradable implants sized for implantation in an ocular region and methods for treating medical conditions of the eye. The implants are formed from a mixture of hydrophilic end and hydrophobic end PLGA, and deliver active agents into an ocular region without a high burst release.
-
公开(公告)号：US09919028B2
公开(公告)日：2018-03-20
申请号：US15171866
申请日：2016-06-02
申请人： Allergan, Inc.
摘要： Disclosed herein are autoclavable formulations of cyclosporin A Form 2, methods of making such formulations, and methods of treating diseases of the eye with such formulations.
-
4.发明申请STEROID-CONTAINING SUSTAINED RELEASE INTRAOCULAR IMPLANTS AND RELATED METHODS 有权STEROID含有持续释放内分泌植入物及相关方法公开(公告)号：US20140322295A1
公开(公告)日：2014-10-30
申请号：US14324948
申请日：2014-07-07
申请人： ALLERGAN, INC.
发明人： Glenn T. Huang , Thierry Nivaggioli , Lon T. Spada , Hiroshi Sugimoto , Wendy M. Blanda , James N. Chang , Orest Olejnik
CPC分类号： A61K9/0051 , A61F9/0017 , A61K9/0024 , A61K9/0092 , A61K9/1647 , A61K9/204 , A61K31/5377 , A61K31/56 , A61K31/573 , A61K31/58 , A61K45/06 , A61K47/593 , A61L27/18 , A61L27/54 , A61L27/58 , A61L31/06 , A61L31/148 , A61L31/16 , A61L2300/222 , A61L2300/436 , A61L2300/45 , A61L2300/604 , A61L2430/16 , A61K2300/00 , C08L67/04
摘要： Biocompatible intraocular implants include a steroid and an auxiliary agent, where the auxiliary agent is present in an amount sufficient to lessen the severity of at least one side effect compared to the use of an otherwise identical implant lacking said auxiliary agent. The steroid and the auxiliary agent may be present on the same intraocular implant or on different implants. The steroid and auxiliary agent may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. Or, the steroid may be associated with a polymeric coating having one or more openings effective to permit the steroid to be released into an external environment. The implants containing the steroid and an auxiliary agent may be placed in an eye to treat one or more ocular conditions while reducing the side effects otherwise accompanying steroid use.
摘要翻译： 生物相容性眼内植入物包括类固醇和辅助剂，其中与使用缺乏所述辅助剂的其它相同的植入物相比，辅助剂的存在量足以减轻至少一种副作用的严重性。 类固醇和辅助剂可以存在于相同的眼内植入物或不同的植入物上。 类固醇和辅助剂可以与可生物降解的聚合物基质相结合，例如两种可生物降解的聚合物的基质。 或者，类固醇可以与具有一个或多个开口有效以允许类固醇释放到外部环境中的聚合物涂层相关联。 包含类固醇和辅助剂的植入物可以放置在眼睛中以治疗一种或多种眼部病症，同时减少否则伴随类固醇使用的副作用。
-
公开(公告)号：US20130123195A1
公开(公告)日：2013-05-16
申请号：US13676551
申请日：2012-11-14
申请人： ALLERGAN, INC.
发明人： Wendy M. Blanda , Mayssa Attar
IPC分类号： A61K38/13
CPC分类号： A61K38/13 , A61K9/0019 , A61K9/0048 , A61K47/32 , A61K47/36 , A61K47/38 , C07K1/306 , C07K7/645
摘要： Disclosed herein are methods of treating diseases of the eye by administering to the subconjunctival space a formulation comprising cyclosporin A form 2 and a hydrogel.
摘要翻译： 本文公开了通过向结膜下空间施用包含环孢菌素A形式2和水凝胶的制剂来治疗眼睛疾病的方法。
-
公开(公告)号：US20130040895A1
公开(公告)日：2013-02-14
申请号：US13652831
申请日：2012-10-16
申请人： ALLERGAN, INC
CPC分类号： A61K9/0051
摘要： Biodegradable drug delivery systems suitable for injection into an ocular region or site and methods for treating ocular conditions. The drug delivery systems provide increased drug residency time and attendant therapeutic benefit.
摘要翻译： 适用于注射到眼睛区域或部位的可生物降解的药物输送系统以及用于治疗眼睛病症的方法。 药物递送系统提供增加的药物驻留时间和伴随的治疗益处。
-
公开(公告)号：US20240238312A1
公开(公告)日：2024-07-18
申请号：US18611454
申请日：2024-03-20
申请人： Allergan, Inc.
发明人： Jane-Guo Shiah , Rahul Bhagat , Wendy M. Blanda , Thierry Nivaggioli , Lin Peng , David Chou , David A. Weber
CPC分类号： A61K31/573 , A61F9/0017 , A61K9/0051 , A61K9/1647 , A61K9/1694 , A61K31/56 , A61K9/204
摘要： The invention provides biodegradable implants sized for implantation in an ocular region and methods for treating medical conditions of the eye. The implants are formed from a mixture of hydrophilic end and hydrophobic end PLGA, and deliver active agents into an ocular region without a high burst release.
-
公开(公告)号：US10076526B2
公开(公告)日：2018-09-18
申请号：US14949454
申请日：2015-11-23
申请人： Allergan, Inc.
发明人： Jane-Guo Shiah , Rahul Bhagat , Wendy M. Blanda , Thierry Nivaggioli , Lin Peng , David Chou , David A. Weber
CPC分类号： A61K31/573 , A61F9/0017 , A61K9/0051 , A61K9/1647 , A61K9/1694 , A61K9/204 , A61K31/56
摘要： The invention provides biodegradable implants sized for implantation in an ocular region and methods for treating medical conditions of the eye. The implants are formed from a mixture of hydrophilic end and hydrophobic end PLGA, and deliver active agents into an ocular region without a high burst release.
-
公开(公告)号：US10076492B2
公开(公告)日：2018-09-18
申请号：US14992592
申请日：2016-01-11
申请人： Allergan, Inc.
发明人： Jeffrey L. Edelman , Patrick M. Hughes , Thomas C. Malone , Gerald W. DeVries , Joan-En Chang-Lin , Jane-Guo Shiah , Thierry Nivaggioli , Lon T. Spada , Wendy M. Blanda
IPC分类号： A61F9/00 , A61K9/00 , A61K31/454 , A61K31/5377 , A61K47/34 , A61K9/20 , A61K31/404
CPC分类号： A61K9/0051 , A61F9/0017 , A61K9/204 , A61K31/404 , A61K31/454 , A61K31/5377 , A61K47/34
摘要： Biocompatible intraocular implants include a tyrosine kinase inhibitor and a biodegradable polymer that is effective to facilitate release of the tyrosine kinase inhibitor into the vitreous of an eye for an extended period of time. The therapeutic agents of the implants may be associated with a biodegradable polymer matrix, such as a matrix that is substantially free of a polyvinyl alcohol. The implants can be placed in an eye to treat or reduce the occurrence of one or more ocular conditions.
-
公开(公告)号：US20180207230A1
公开(公告)日：2018-07-26
申请号：US15925272
申请日：2018-03-19
申请人： Allergan, Inc.
摘要： Disclosed herein are autoclavable formulations of cyclosporin A Form 2, methods of making such formulations, and methods of treating diseases of the eye with such formulations.
-
-
-
-
-
-
-
-
-
搜索结果
43 条记录 (耗时 0.021 秒)
